{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:40:43Z","timestamp":1770889243449,"version":"3.50.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017956","name":"Health Commission of Gansu Province","doi-asserted-by":"publisher","award":["No. GSWSKY2025-086"],"award-info":[{"award-number":["No. GSWSKY2025-086"]}],"id":[{"id":"10.13039\/100017956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00417-025-06925-3","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:55Z","timestamp":1760773615000},"page":"3331-3345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nonadherence to anti-VEGF intravitreal injections in patients with diabetic macular edema"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8113-6502","authenticated-orcid":false,"given":"Yang","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2456-485X","authenticated-orcid":false,"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2751-3154","authenticated-orcid":false,"given":"Fu-hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1688-9268","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"6925_CR1","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.2147\/OPTH.S318026","volume":"15","author":"J Figueira","year":"2021","unstructured":"Figueira J, Henriques J, Carneiro \u00c2 et al (2021) Guidelines for the management of center-Involving diabetic macular edema: treatment options and patient monitorization. Clin Ophthalmol 15:3221\u20133230. https:\/\/doi.org\/10.2147\/OPTH.S318026","journal-title":"Clin Ophthalmol"},{"issue":"S1","key":"6925_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.53","volume":"31","author":"R Gale","year":"2017","unstructured":"Gale R, Scanlon PH, Evans M et al (2017) Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. Eye (Lond) 31(S1):S1\u2013S20. https:\/\/doi.org\/10.1038\/eye.2017.53","journal-title":"Eye (Lond)"},{"key":"6925_CR3","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.2147\/OPTH.S320948","volume":"15","author":"P Udaondo","year":"2021","unstructured":"Udaondo P, Adan A, Arias-Barquet L et al (2021) Challenges in diabetic macular edema management: an expert consensus report. Clin Ophthalmol 3183\u20133195. https:\/\/doi.org\/10.2147\/OPTH.S320948","journal-title":"Clin Ophthalmol"},{"key":"6925_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/IAE.0000000000004096","volume":"44","author":"D Zur","year":"2024","unstructured":"Zur D, Hod K, Trivizki O et al (2024) Anti-vascular endothelial growth factor\u2002treatment in diabetic macular edema: results from a large single-center cohort with bevacizumab as first-line therapy. Retina 44:1305\u20131313. https:\/\/doi.org\/10.1097\/IAE.0000000000004096","journal-title":"Retina"},{"key":"6925_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40200-022-01049-5","volume":"21","author":"P Zhou","year":"2022","unstructured":"Zhou P, Gao J, Huang X et al (2022) Impact of the COVID-19 pandemic on visual outcomes of diabetic macular edema patients at a tertiary care veterans affairs center. J Diabetes Metab Disord 21:759\u2013768. https:\/\/doi.org\/10.1007\/s40200-022-01049-5","journal-title":"J Diabetes Metab Disord"},{"key":"6925_CR6","doi-asserted-by":"publisher","first-page":"6654168","DOI":"10.1155\/2021\/6654168","volume":"2021","author":"C Furino","year":"2021","unstructured":"Furino C, Boscia F, Reibaldi M et al (2021) Intravitreal therapy for diabetic macular edema: an update. J Ophthalmol 2021:6654168","journal-title":"J Ophthalmol"},{"key":"6925_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000512300","volume":"64","author":"J Choovuthayakorn","year":"2021","unstructured":"Choovuthayakorn J, Phinyo P, Tantraworasin A et al (2021) Intravitreal anti-vascular endothelial growth factor therapy for diabetic macular edema in clinical practice of single center: three-year outcomes. Ophthalmic Res 64:483\u2013493. https:\/\/doi.org\/10.1159\/000512300","journal-title":"Ophthalmic Res"},{"key":"6925_CR8","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1007\/s00417-024-06558-y","volume":"262","author":"S Nakao","year":"2024","unstructured":"Nakao S, Kusuhara S, Murakami T (2024) Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology. Graefes Arch Clin Exp Ophthalmol 262:3749\u20133759. https:\/\/doi.org\/10.1007\/s00417-024-06558-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR9","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s12325-017-0548-1","volume":"34","author":"N Dervenis","year":"2017","unstructured":"Dervenis N, Mikropoulou AM, Tranos P, Dervenis P (2017) Ranibizumab in the treatment of diabetic macular edema: a review of the current status, unmet needs, and emerging challenges. Adv Ther 34:1270\u20131282. https:\/\/doi.org\/10.1007\/s12325-017-0548-1","journal-title":"Adv Ther"},{"key":"6925_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T et al (2022) Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence 16:587\u2013604. https:\/\/doi.org\/10.2147\/PPA.S347713","journal-title":"Patient Prefer Adherence"},{"key":"6925_CR11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Bracha P, Pollack J, Williams DF (2018) Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina 2:1179\u20131187. https:\/\/doi.org\/10.1016\/j.oret.2018.06.004","journal-title":"Ophthalmol Retina"},{"key":"6925_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde OA, Patel PJ (2023) Real-world outcomes of anti-VEGF therapy in diabetic macular oedema: barriers to treatment success and implications for low\/lower-middle-income countries. Ophthalmol Ther 12:809\u2013826. https:\/\/doi.org\/10.1007\/s40123-023-00672-6","journal-title":"Ophthalmol Ther"},{"key":"6925_CR13","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s40123-024-01026-6","volume":"13","author":"T Hirano","year":"2024","unstructured":"Hirano T, Tanabe K, Murata T (2024) Factors influencing treatment preference in patients with diabetic macular edema: a study using conjoint analysis. Ophthalmol Ther 13:2887\u20132901. https:\/\/doi.org\/10.1007\/s40123-024-01026-6","journal-title":"Ophthalmol Ther"},{"key":"6925_CR14","doi-asserted-by":"publisher","first-page":"8825082","DOI":"10.1155\/2021\/8825082","volume":"2021","author":"T Naujokaitis","year":"2021","unstructured":"Naujokaitis T, Balciuniene VJ (2021) Real-world treatment patterns and vision outcomes with ranibizumab for diabetic macular edema. J Ophthalmol 2021:8825082","journal-title":"J Ophthalmol"},{"key":"6925_CR15","doi-asserted-by":"publisher","first-page":"e0233595","DOI":"10.1371\/journal.pone.0233595","volume":"15","author":"P Mitchell","year":"2020","unstructured":"Mitchell P, Sheidow TG, Farah ME et al (2020) Effectiveness and safety of ranibizumab 0.5\u00a0mg in treatment-na\u00efve patients with diabetic macular edema: results from the real-world global LUMINOUS study. PLoS One 15:e0233595. https:\/\/doi.org\/10.1371\/journal.pone.0233595","journal-title":"PLoS One"},{"key":"6925_CR16","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2147\/OPTH.S60893","volume":"8","author":"S Kiss","year":"2014","unstructured":"Kiss S, Liu Y, Brown J et al (2014) Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol 8:1611\u20131621. https:\/\/doi.org\/10.2147\/OPTH.S60893","journal-title":"Clin Ophthalmol"},{"key":"6925_CR17","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1007\/s10792-022-02375-6","volume":"42","author":"AH Durukan","year":"2022","unstructured":"Durukan AH, Unlu N, Onen M et al (2022) Anti-vascular endothelial growth factor therapy in diabetic macular edema: real-life outcomes from a multicenter study in Turkey over 36 months. Int Ophthalmol 42:3777\u20133787. https:\/\/doi.org\/10.1007\/s10792-022-02375-6","journal-title":"Int Ophthalmol"},{"key":"6925_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2017","unstructured":"Ehlken C, Helms M, B\u00f6hringer D, Agostini HT, Stahl A (2017) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13\u201320. https:\/\/doi.org\/10.2147\/OPTH.S151611","journal-title":"Clin Ophthalmol"},{"key":"6925_CR19","doi-asserted-by":"publisher","first-page":"205031212311996","DOI":"10.1177\/20503121231199655","volume":"11","author":"VKL Takahashi","year":"2023","unstructured":"Takahashi VKL, Balbino M, Ruppert ADP et al (2023) Lost to follow-up of patients who received intravitreal anti-vascular endothelial growth factor therapy to treat four different retina disorders in an individual center in Brazil. SAGE Open Med 11:20503121231199655. https:\/\/doi.org\/10.1177\/20503121231199655","journal-title":"SAGE Open Med"},{"key":"6925_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40942-023-00463-y","volume":"9","author":"SP Chitturi","year":"2023","unstructured":"Chitturi SP, Venkatesh R, Mangla R et al (2023) REal-world treatment outcomes after delayed intravitreal therapy in center-involving diabetic macular edema - RETORT study. Int J Retina Vitreous 9:22. https:\/\/doi.org\/10.1186\/s40942-023-00463-y","journal-title":"Int J Retina Vitreous"},{"key":"6925_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/IAE.0000000000003037","volume":"41","author":"A Watane","year":"2021","unstructured":"Watane A, Kalavar M, Vanner EA et al (2021) Follow-up adherence in patients with nonproliferative diabetic retinopathy presening to an ophthalmic emergency department. Retina 41:1293\u20131301. https:\/\/doi.org\/10.1097\/IAE.0000000000003037","journal-title":"Retina"},{"key":"6925_CR22","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/ceo.13845","volume":"48","author":"MA Rose","year":"2020","unstructured":"Rose MA, Vukicevic M, Koklanis K (2020) Adherence of patients with diabetic macular oedema to intravitreal injections: a systematic review. Clin Exp Ophthalmol 48:1286\u20131298. https:\/\/doi.org\/10.1111\/ceo.13845","journal-title":"Clin Exp Ophthalmol"},{"key":"6925_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000538975","volume":"67","author":"N Holekamp","year":"2024","unstructured":"Holekamp N, Gentile B, Giocanti-Aur\u00e9gan A et al (2024) Patient experience survey of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration and diabetic macular edema. Ophthalmic Res 67:311\u2013321. https:\/\/doi.org\/10.1159\/000538975","journal-title":"Ophthalmic Res"},{"key":"6925_CR24","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N et al (2020) Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol 258:2077\u20132090. https:\/\/doi.org\/10.1007\/s00417-020-04798-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR25","doi-asserted-by":"publisher","first-page":"18353","DOI":"10.1038\/s41598-021-97644-2","volume":"11","author":"JS Kim","year":"2021","unstructured":"Kim JS, Lee S, Kim JY et al (2021) Visual\/anatomical outcome of diabetic macular edema patients lost to follow-up for more than 1 year. Sci Rep 11:18353. https:\/\/doi.org\/10.1038\/s41598-021-97644-2","journal-title":"Sci Rep"},{"key":"6925_CR26","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1111\/aos.14946","volume":"100","author":"R Angermann","year":"2022","unstructured":"Angermann R, Hofer M, Huber AL et al (2022) The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up study. Acta Ophthalmol 100:e546\u2013e552. https:\/\/doi.org\/10.1111\/aos.14946","journal-title":"Acta Ophthalmol"},{"key":"6925_CR27","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s40123-023-00750-9","volume":"12","author":"SJ Bakri","year":"2023","unstructured":"Bakri SJ, Delyfer MN, Grauslund J et al (2023) Real-world persistence and treatment interval in patients with diabetic macular edema treated with anti-vascular endothelial growth factors in the USA. Ophthalmol Ther 12:2465\u20132477. https:\/\/doi.org\/10.1007\/s40123-023-00750-9","journal-title":"Ophthalmol Ther"},{"key":"6925_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3928\/23258160-20180221-06","volume":"49","author":"ME Jansen","year":"2018","unstructured":"Jansen ME, Krambeer CJ, Kermany DS et al (2018) Appointment compliance in patients with diabetic macular edema and exudative macular degeneration. Ophthalmic Surg Lasers Imaging Retina 49:186\u2013190. https:\/\/doi.org\/10.3928\/23258160-20180221-06","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6925_CR29","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.2147\/OPTH.S313081","volume":"15","author":"L Kodjikian","year":"2021","unstructured":"Kodjikian L, Lecleire-Collet A, Dot C et al (2021) ETOILE: real-world evidence of 24 months of Ranibizumab 0.5\u00a0mg in patients with visual impairment due to diabetic macular edema. Clin Ophthalmol 2307\u20132315. https:\/\/doi.org\/10.2147\/OPTH.S313081","journal-title":"Clin Ophthalmol"},{"key":"6925_CR30","doi-asserted-by":"publisher","first-page":"4610129","DOI":"10.1155\/2018\/4610129","volume":"2018","author":"AL Best","year":"2018","unstructured":"Best AL, Fajnkuchen F, Nghiem-Buffet S et al (2018) Treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting. J Ophthalmol 2018:4610129","journal-title":"J Ophthalmol"},{"key":"6925_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.oret.2018.11.002","volume":"3","author":"X Gao","year":"2019","unstructured":"Gao X, Obeid A, Aderman CM et al (2019) Loss to follow-up after intravitreal anti-vascular endothelial growth factor injections in patients with diabetic macular edema. Ophthalmol Retina 3:230\u2013236. https:\/\/doi.org\/10.1016\/j.oret.2018.11.002","journal-title":"Ophthalmol Retina"},{"key":"6925_CR32","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","volume":"38","author":"M Weiss","year":"2018","unstructured":"Weiss M, Sim DA, Herold T et al (2018) Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina 38:2293\u20132300. https:\/\/doi.org\/10.1097\/IAE.0000000000001892","journal-title":"Retina"},{"key":"6925_CR33","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00592-020-01513-9","volume":"57","author":"F Fajnkuchen","year":"2020","unstructured":"Fajnkuchen F, Delyfer MN, Conrath J et al (2020) Expectations and fears of patients with diabetes and macular edema treated by intravitreal injections. Acta Diabetol 57:1081\u20131091. https:\/\/doi.org\/10.1007\/s00592-020-01513-9","journal-title":"Acta Diabetol"},{"key":"6925_CR34","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00417-020-04944-w","volume":"259","author":"MS Ramakrishnan","year":"2021","unstructured":"Ramakrishnan MS, Yu Y, VanderBeek BL (2021) Visit adherence and visual acuity outcomes in patients with diabetic macular edema: a secondary analysis of DRCRnet protocol T. Graefes Arch Clin Exp Ophthalmol 259:1419\u20131425. https:\/\/doi.org\/10.1007\/s00417-020-04944-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40942-022-00380-6","volume":"8","author":"ACS Tan","year":"2022","unstructured":"Tan ACS, Schwartz R, Anaya D et al (2022) Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations. Int J Retina Vitreous 8:33. https:\/\/doi.org\/10.1186\/s40942-022-00380-6","journal-title":"Int J Retina Vitreous"},{"key":"6925_CR36","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1007\/s42399-020-00614-4","volume":"2","author":"LM Wasser","year":"2020","unstructured":"Wasser LM, Weill Y, Brosh K et al (2020) The impact of COVID-19 on intravitreal injection compliance. SN Compr Clin Med 2:2546\u20132549. https:\/\/doi.org\/10.1007\/s42399-020-00614-4","journal-title":"SN Compr Clin Med"},{"key":"6925_CR37","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00417-021-05549-7","volume":"260","author":"A Navarrete","year":"2022","unstructured":"Navarrete A, Vofo B, Matos K et al (2022) The detrimental effects of delayed intravitreal anti-VEGF therapy for treating retinal pathology: lessons from a forced test-case. Graefes Arch Clin Exp Ophthalmol 260:2201\u20132208. https:\/\/doi.org\/10.1007\/s00417-021-05549-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR38","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1007\/s00417-020-04858-7","volume":"258","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Grosso D, Vella G et al (2020) Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let\u2019s be ready for a plausible rebound effect. Graefes Arch Clin Exp Ophthalmol 258:2655\u20132660. https:\/\/doi.org\/10.1007\/s00417-020-04858-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/1120672120962032","volume":"31","author":"A Carnevali","year":"2021","unstructured":"Carnevali A, Giannaccare G, Gatti V et al (2021) Intravitreal injections during COVID-19 outbreak: real-world experience from an Italian tertiary referral center. Eur J Ophthalmol 31:10\u201312. https:\/\/doi.org\/10.1177\/1120672120962032","journal-title":"Eur J Ophthalmol"},{"key":"6925_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/aos.15206","volume":"101","author":"V Hurand","year":"2023","unstructured":"Hurand V, Ducloyer JB, Baudin F et al (2023) IMPACT study: impact of adherence to anti-VEGF intravitreal injections for macular disease during COVID 19-related confinement in France. Acta Ophthalmol 101:91\u201399. https:\/\/doi.org\/10.1111\/aos.15206","journal-title":"Acta Ophthalmol"},{"key":"6925_CR41","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.oret.2020.12.020","volume":"5","author":"W Song","year":"2021","unstructured":"Song W, Singh RP, Rachitskaya AV (2021) The effect of delay in care among patients requiring intravitreal injections. Ophthalmol Retina 5:975\u2013980. https:\/\/doi.org\/10.1016\/j.oret.2020.12.020","journal-title":"Ophthalmol Retina"},{"key":"6925_CR42","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1097\/IAE.0000000000003276","volume":"41","author":"RB Rush","year":"2021","unstructured":"Rush RB, Rush SW (2021) Outcomes in patients resuming intravitreal anti-VEGF therapy following treatment delay during the COVID-19 pandemic. Retina 41:2456\u20132461. https:\/\/doi.org\/10.1097\/IAE.0000000000003276","journal-title":"Retina"},{"key":"6925_CR43","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.2147\/OPTH.S269179","volume":"14","author":"OA Saleh","year":"2020","unstructured":"Saleh OA, Jammal H, Alqudah N et al (2020) Clinical experience in the administration of intravitreal injection therapy at a tertiary university hospital in Jordan during the COVID-19 lockdown. Clin Ophthalmol 2473\u20132480. https:\/\/doi.org\/10.2147\/OPTH.S269179","journal-title":"Clin Ophthalmol"},{"key":"6925_CR44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S et al (2023) Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev 12:92. https:\/\/doi.org\/10.1186\/s13643-023-02261-x","journal-title":"Syst Rev"},{"key":"6925_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12886-019-1191-1","volume":"19","author":"S Jandorf","year":"2019","unstructured":"Jandorf S, Krogh Nielsen M, S\u00f8rensen K et al (2019) Low health literacy levels in patients with chronic retinal disease. BMC Ophthalmol 19:174. https:\/\/doi.org\/10.1186\/s12886-019-1191-1","journal-title":"BMC Ophthalmol"},{"key":"6925_CR46","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2147\/OPTH.S248661","volume":"14","author":"NE Abu-Yaghi","year":"2020","unstructured":"Abu-Yaghi NE, Abed AM, Khlaifat DF et al (2020) Factors affecting compliance to anti-vascular endothelial growth factor treatment of diabetic macular edema in a cohort of Jordanian patients. Clin Ophthalmol 921\u2013929. https:\/\/doi.org\/10.2147\/OPTH.S248661","journal-title":"Clin Ophthalmol"},{"key":"6925_CR47","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3928\/23258160-20210904-01","volume":"52","author":"CN Shields","year":"2021","unstructured":"Shields CN, Cherkas EG, Mokhashi N et al (2021) Barriers to follow-up retinal care during the COVID-19 pandemic: a survey study. Ophthalmic Surg Lasers Imaging Retina 52:526\u2013533. https:\/\/doi.org\/10.3928\/23258160-20210904-01","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6925_CR48","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.survophthal.2022.08.002","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R et al (2022) Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: a systematic review and meta-analysis. Surv Ophthalmol 67:1593\u20131602. https:\/\/doi.org\/10.1016\/j.survophthal.2022.08.002","journal-title":"Surv Ophthalmol"},{"key":"6925_CR49","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10792-021-01719-y","volume":"41","author":"M Moussa","year":"2021","unstructured":"Moussa M, Elshorbagy MS, Emarah A et al (2021) Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta university hospital. Int Ophthalmol 41:1437\u20131443. https:\/\/doi.org\/10.1007\/s10792-021-01719-y","journal-title":"Int Ophthalmol"},{"key":"6925_CR50","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/11206721211002442","volume":"32","author":"R Dell\u2019Omo","year":"2021","unstructured":"Dell\u2019Omo R, Filippelli M, Virgili G et al (2021) Effect of COVID-19-related lockdown on ophthalmic practice in Italy: a report from 39 institutional centers. Eur J Ophthalmol 32:695\u2013703. https:\/\/doi.org\/10.1177\/11206721211002442","journal-title":"Eur J Ophthalmol"},{"key":"6925_CR51","doi-asserted-by":"publisher","first-page":"6794","DOI":"10.3390\/jcm11226794","volume":"11","author":"R Komori","year":"2022","unstructured":"Komori R, Takamura Y, Yamada Y et al (2022) Impact of the COVID-19 pandemic on anti-vascular endothelial growth factor therapy for diabetic macular edema in Japan. J Clin Med 11:6794. https:\/\/doi.org\/10.3390\/jcm11226794","journal-title":"J Clin Med"},{"key":"6925_CR52","doi-asserted-by":"publisher","first-page":"670468","DOI":"10.3389\/fphar.2021.670468","volume":"12","author":"C Iovino","year":"2021","unstructured":"Iovino C, Peiretti E, Giannaccare G et al (2021) Evolving treatment paradigm in the management of diabetic macular edema in the era of COVID-19. Front Pharmacol 12:670468. https:\/\/doi.org\/10.3389\/fphar.2021.670468","journal-title":"Front Pharmacol"},{"key":"6925_CR53","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","volume":"68","author":"A Kelkar","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R et al (2020) Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol 68:2143\u20132147. https:\/\/doi.org\/10.4103\/ijo.IJO_1866_19","journal-title":"Indian J Ophthalmol"},{"key":"6925_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00417-021-05246-5","volume":"260","author":"TR Rosenblatt","year":"2022","unstructured":"Rosenblatt TR, Rayess N, Al-Moujahed A et al (2022) Discontinuation and loss to follow-up rates in clinical trials of intravitreal anti-vascular endothelial growth factor injections. Graefes Arch Clin Exp Ophthalmol 260:93\u2013100. https:\/\/doi.org\/10.1007\/s00417-021-05246-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR55","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/02713683.2018.1543708","volume":"44","author":"AE Habib","year":"2019","unstructured":"Habib AE, Abdel-Kader AA, Eissa IM et al (2019) Adherence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) drugs in diabetic macular edema in an Egyptian population: a health belief model. Curr Eye Res 44:303\u2013310. https:\/\/doi.org\/10.1080\/02713683.2018.1543708","journal-title":"Curr Eye Res"},{"key":"6925_CR56","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3928\/23258160-20210330-04","volume":"52","author":"D Agarwal","year":"2021","unstructured":"Agarwal D, Udeh B, Campbell J et al (2021) Follow-up appointment delay in diabetic macular edema patients. Ophthalmic Surg Lasers Imaging Retina 52:200\u2013206. https:\/\/doi.org\/10.3928\/23258160-20210330-04","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6925_CR57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12886-016-0317-y","volume":"16","author":"A Giocanti-Auregan","year":"2016","unstructured":"Giocanti-Auregan A, Tadayoni R, Grenet T et al (2016) Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmol 16:142. https:\/\/doi.org\/10.1186\/s12886-016-0317-y","journal-title":"BMC Ophthalmol"},{"key":"6925_CR58","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s00417-021-05108-0","volume":"259","author":"S Ness","year":"2021","unstructured":"Ness S, Green M, Loporchio D et al (2021) Risk factors for fellow eye treatment in protocol T. Graefes Arch Clin Exp Ophthalmol 259:2203\u20132212. https:\/\/doi.org\/10.1007\/s00417-021-05108-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR59","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/IAE.0000000000002941","volume":"41","author":"F Viola","year":"2021","unstructured":"Viola F, Milella P, Pozzo Giuffrida F et al (2021) Impact of coronavirus disease pandemic on intravitreal injections treatment for macular diseases: report from a referral hospital in Milan. Retina 41:701\u2013705. https:\/\/doi.org\/10.1097\/IAE.0000000000002941","journal-title":"Retina"},{"key":"6925_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.35119\/myjo.v3i2.174","volume":"3","author":"YM Wong","year":"2021","unstructured":"Wong YM, Chong EL, Yeo VY (2021) Non-compliance among diabetic macular oedema patients on antivascular endothelial growth factor therapy in Malaysia. Malaysian J Ophthalmol 3:91\u2013100. https:\/\/doi.org\/10.35119\/myjo.v3i2.174","journal-title":"Malaysian J Ophthalmol"},{"key":"6925_CR61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40942-021-00311-x","volume":"7","author":"S M\u00fcller","year":"2021","unstructured":"M\u00fcller S, Junker S, Wilke T et al (2021) Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT. Int J Retina Vitreous 7:43. https:\/\/doi.org\/10.1186\/s40942-021-00311-x","journal-title":"Int J Retina Vitreous"},{"key":"6925_CR62","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.2147\/OPTH.S114006","volume":"10","author":"S Kiss","year":"2016","unstructured":"Kiss S, Chandwani HS, Cole AL et al (2016) Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clin Ophthalmol 2443\u20132453. https:\/\/doi.org\/10.2147\/OPTH.S114006","journal-title":"Clin Ophthalmol"},{"key":"6925_CR63","doi-asserted-by":"publisher","first-page":"e44340","DOI":"10.7759\/cureus.44340","volume":"15","author":"AD Alharbi","year":"2023","unstructured":"Alharbi AD, Alotayk NI, Alaboudi AA et al (2023) Prevalence and visual consequences of non-adherent patients receiving anti-vascular endothelial growth factor (VEGF) injections at King Fahad specialist hospital (KFSH), Qassim region. Cureus 15:e44340. https:\/\/doi.org\/10.7759\/cureus.44340","journal-title":"Cureus"},{"key":"6925_CR64","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00417-020-04936-w","volume":"259","author":"S Yoshida","year":"2021","unstructured":"Yoshida S, Murakami T, Nozaki M et al (2021) Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 259:815\u2013836. https:\/\/doi.org\/10.1007\/s00417-020-04936-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR65","doi-asserted-by":"publisher","first-page":"A844","DOI":"10.1016\/j.jval.2016.08.508","volume":"19","author":"R Schnabel","year":"2016","unstructured":"Schnabel R, Tan J, Cullip T et al (2016) Barriers to initravitreal injection therapy adherence in Dme patients in Australia. Value Health 19:A844. https:\/\/doi.org\/10.1016\/j.jval.2016.08.508","journal-title":"Value Health"},{"key":"6925_CR66","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1111\/aos.14514","volume":"99","author":"J Cao","year":"2021","unstructured":"Cao J, You K, Jin K et al (2021) Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method. Acta Ophthalmol 99:e19\u2013e27. https:\/\/doi.org\/10.1111\/aos.14514","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"6925_CR67","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/jdi.13801","volume":"13","author":"S Kusuhara","year":"2022","unstructured":"Kusuhara S, Shimura M, Kitano S et al (2022) Treatment of diabetic macular edema in real-world clinical practice: the effect of aging. J Diabetes Investig 13(8):1339\u20131346. https:\/\/doi.org\/10.1111\/jdi.13801","journal-title":"J Diabetes Investig"},{"issue":"8","key":"6925_CR68","doi-asserted-by":"publisher","first-page":"e1630","DOI":"10.1111\/aos.15151","volume":"100","author":"SN Hertzberg","year":"2022","unstructured":"Hertzberg SN, Moe MC, J\u00f8rstad \u00d8K et al (2022) Healthcare expenditure of intravitreal anti-vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema. Acta Ophthalmol 100(8):e1630\u2013e1640. https:\/\/doi.org\/10.1111\/aos.15151","journal-title":"Acta Ophthalmol"},{"key":"6925_CR69","doi-asserted-by":"publisher","first-page":"7194927","DOI":"10.1155\/2017\/7194927","volume":"2017","author":"Y Subhi","year":"2017","unstructured":"Subhi Y, S\u00f8rensen TL (2017) Neovascular Age-Related macular degeneration in the very old (\u2265\u200990 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy. J Ophthalmol 2017:7194927. https:\/\/doi.org\/10.1155\/2017\/7194927","journal-title":"J Ophthalmol"},{"issue":"1","key":"6925_CR70","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000543352","volume":"68","author":"E Naaman","year":"2025","unstructured":"Naaman E, Yanir-Prat N, Shair-Nakhleh D et al (2025) Exploring factors behind patient nonadherence to intravitreal anti-vascular endothelial growth factor injections in macular diseases. Ophthalmic Res 68(1):221\u2013227. https:\/\/doi.org\/10.1159\/000543352","journal-title":"Ophthalmic Res"},{"key":"6925_CR71","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4149\/BLL_2024_40","volume":"125","author":"P Schnorrerova","year":"2024","unstructured":"Schnorrerova P, Matalova P, Wawruch M (2024) Medication adherence: measurement methods and approaches. Bratisl Lek Listy 125:264\u2013273. https:\/\/doi.org\/10.4149\/BLL_2024_40","journal-title":"Bratisl Lek Listy"},{"key":"6925_CR72","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000953","volume":"34","author":"J Hovanesian","year":"2023","unstructured":"Hovanesian J, Singh IP, Bauskar A (2023) Identifying and addressing common contributors to nonadherence with ophthalmic medical therapy. Curr Opin Ophthalmol 34:S1\u2013S. https:\/\/doi.org\/10.1097\/ICU.0000000000000953","journal-title":"Curr Opin Ophthalmol"},{"key":"6925_CR73","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","volume":"258","author":"JF Korobelnik","year":"2020","unstructured":"Korobelnik JF, Loewenstein A, Eldem B et al (2020) Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 258:1149\u20131156. https:\/\/doi.org\/10.1007\/s00417-020-04703-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR74","unstructured":"American Academy of Ophthalmology (2020) Important coronavirus updates for ophthalmologists. Available at: https:\/\/www.aao.org\/headline\/alert-important-coronavirus-context. Accessed March 31"},{"key":"6925_CR75","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1177\/1120672120953074","volume":"31","author":"R Dell\u2019Omo","year":"2021","unstructured":"Dell\u2019Omo R, Filippelli M, Semeraro F et al (2021) Effects of the first month of lockdown for COVID-19 in Italy: a preliminary analysis on the eyecare system from six centers. Eur J Ophthalmol 31:2252\u20132258. https:\/\/doi.org\/10.1177\/1120672120953074","journal-title":"Eur J Ophthalmol"},{"key":"6925_CR76","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12886-022-02349-3","volume":"22","author":"N Dhillon","year":"2022","unstructured":"Dhillon N, Santiago C (2022) Management of acute proliferative diabetic retinopathy related complications during the first COVID-19 wave. BMC Ophthalmol 22:119. https:\/\/doi.org\/10.1186\/s12886-022-02349-3","journal-title":"BMC Ophthalmol"},{"key":"6925_CR77","doi-asserted-by":"publisher","first-page":"939315","DOI":"10.1155\/2014\/939315","volume":"2014","author":"JR Gonder","year":"2014","unstructured":"Gonder JR, Walker VM, Barbeau M et al (2014) Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY). J Ophthalmol 2014:939315. https:\/\/doi.org\/10.1155\/2014\/939315","journal-title":"J Ophthalmol"},{"key":"6925_CR78","doi-asserted-by":"publisher","first-page":"336","DOI":"10.28982\/josam.941790","volume":"6","author":"H \u00d6nc\u00fcl","year":"2022","unstructured":"\u00d6nc\u00fcl H, Y\u0131lmaz \u00d6nc\u00fcl F, Alaku\u015f F (2022) Diabetic retinopathy treatment and management during the COVID-19 pandemic. J Surg Med 6:336\u2013341. https:\/\/doi.org\/10.28982\/josam.941790","journal-title":"J Surg Med"},{"key":"6925_CR79","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s00417-020-04849-8","volume":"258","author":"LG Stone","year":"2020","unstructured":"Stone LG, Devenport A, Stratton IM et al (2020) Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19. Graefes Arch Clin Exp Ophthalmol 258:2639\u20132645. https:\/\/doi.org\/10.1007\/s00417-020-04849-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR80","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/OPTH.S289068","volume":"15","author":"M Elfalah","year":"2021","unstructured":"Elfalah M, AlRyalat SA, Toro MD et al (2021) Delayed intravitreal anti-VEGF therapy for patients during the COVID-19 lockdown: an ethical endeavor. Clin Ophthalmol 661\u2013669. https:\/\/doi.org\/10.2147\/OPTH.S289068","journal-title":"Clin Ophthalmol"},{"key":"6925_CR81","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/dme.12593","volume":"32","author":"PH Scanlon","year":"2015","unstructured":"Scanlon PH, Loftus J, Starita C et al (2015) The use of weighted health-related quality of life scores in people with diabetic macular oedema at baseline in a randomized clinical trial. Diabet Med 32:97\u2013101. https:\/\/doi.org\/10.1111\/dme.12593","journal-title":"Diabet Med"},{"key":"6925_CR82","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/JCMA.0000000000000588","volume":"84","author":"CC Weng","year":"2021","unstructured":"Weng CC, Lin TY, Yang YP et al (2021) Modifications of intravitreal injections in response to the COVID-19 pandemic. J Chin Med Assoc 84:827\u2013832. https:\/\/doi.org\/10.1097\/JCMA.0000000000000588","journal-title":"J Chin Med Assoc"},{"key":"6925_CR83","doi-asserted-by":"publisher","first-page":"781421","DOI":"10.3389\/fmed.2021.781421","volume":"8","author":"TT Lai","year":"2022","unstructured":"Lai TT, Chen TC, Yang CH et al (2022) Treat-and-extend vs. pro re Nata regimen of Ranibizumab for diabetic macular edema-a two-year matched comparative study. Front Med (Lausanne) 8:781421. https:\/\/doi.org\/10.3389\/fmed.2021.781421","journal-title":"Front Med (Lausanne)"},{"key":"6925_CR84","doi-asserted-by":"publisher","first-page":"e000696","DOI":"10.1136\/bmjophth-2020-000696","volume":"6","author":"L Downey","year":"2021","unstructured":"Downey L, Acharya N, Devonport H et al (2021) Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. BMJ Open Ophthalmol 6:e000696. https:\/\/doi.org\/10.1136\/bmjophth-2020-000696","journal-title":"BMJ Open Ophthalmol"},{"key":"6925_CR85","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40123-021-00395-6","volume":"10","author":"V corcia","year":"2021","unstructured":"corcia V, Giannaccare G, Gatti V et al (2021) Intravitreal dexamethasone implant in patients who did not complete anti-VEGF loading dose during the COVID-19 pandemic: a retrospective observational study. Ophthalmol Ther 10:1015\u20131024. https:\/\/doi.org\/10.1007\/s40123-021-00395-6","journal-title":"Ophthalmol Ther"},{"key":"6925_CR86","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.4103\/IJO.IJO_220_23","volume":"71","author":"G Kumar","year":"2023","unstructured":"Kumar G, Velu S, Rajalakshmi R et al (2023) Compliance with follow-up in patients with diabetic macular edema: eye care center vs. diabetes care center. Indian J Ophthalmol 71:2531\u20132536. https:\/\/doi.org\/10.4103\/IJO.IJO_220_23","journal-title":"Indian J Ophthalmol"},{"key":"6925_CR87","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40942-020-00226-z","volume":"6","author":"P Corazza","year":"2020","unstructured":"Corazza P, D\u2019Alterio FM, Younis S (2020) Proposed algorithm during COVID-19 pandemic for patient management in medical retina clinic. Int J Retina Vitreous 6:20. https:\/\/doi.org\/10.1186\/s40942-020-00226-z","journal-title":"Int J Retina Vitreous"},{"key":"6925_CR88","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/eye.2016.18","volume":"30","author":"JM Baxter","year":"2016","unstructured":"Baxter JM, Fotheringham AJ, Foss AJ (2016) Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye (Lond) 30:698\u2013704. https:\/\/doi.org\/10.1038\/eye.2016.18","journal-title":"Eye (Lond)"},{"key":"6925_CR89","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/IAE.0000000000001681","volume":"38","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Wilke T, Bauer-Steinhusen U et al (2018) Treatment of neovascular age-related macular degeneration patients with vascular endothelial growth factor inhbitors in everyday practice: identification of health care constraints in Germany-the PONS study. Retina 38:1134\u20131144. https:\/\/doi.org\/10.1097\/IAE.0000000000001681","journal-title":"Retina"},{"key":"6925_CR90","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1007\/s00417-023-06108-y","volume":"261","author":"D Veritti","year":"2023","unstructured":"Veritti D, Sarao V, Chhablani J et al (2023) The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey. Graefes Arch Clin Exp Ophthalmol 261:3299\u20133306. https:\/\/doi.org\/10.1007\/s00417-023-06108-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR91","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1177\/11206721221078554","volume":"32","author":"G Scarpa","year":"2022","unstructured":"Scarpa G, Urban F, Scarpa M et al (2022) Intravitreal injections during the COVID-19 outbreak in Northern Italy: an innovative approach for a high quality and safe treatment. Eur J Ophthalmol 32:3667\u20133673. https:\/\/doi.org\/10.1177\/11206721221078554","journal-title":"Eur J Ophthalmol"},{"key":"6925_CR92","doi-asserted-by":"publisher","first-page":"100900","DOI":"10.1016\/j.preteyeres.2020.100900","volume":"82","author":"JO Li","year":"2021","unstructured":"Li JO, Liu H, Ting DSJ et al (2021) Digital technology, tele-medicine and artificial intelligence in ophthalmology: a global perspective. Prog Retin Eye Res 82:100900. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100900","journal-title":"Prog Retin Eye Res"},{"key":"6925_CR93","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/11206721221123884","volume":"33","author":"L Bellot","year":"2023","unstructured":"Bellot L, Anthony N, Maucourant Y (2023) Evaluation of remote assessment reliability in the follow-up of patients with diabetic macular edema. Eur J Ophthalmol 33:1026\u20131032","journal-title":"Eur J Ophthalmol"},{"key":"6925_CR94","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bjophthalmol-2020-317683","volume":"106","author":"YC Tham","year":"2022","unstructured":"Tham YC, Husain R, Teo KYC et al (2022) New digital models of care in ophthalmology, during and beyond the COVID-19 pandemic. Br J Ophthalmol 106:452\u2013457. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317683","journal-title":"Br J Ophthalmol"},{"key":"6925_CR95","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jamaophthalmol.2023.2271","volume":"141","author":"W Paul","year":"2023","unstructured":"Paul W, Burlina P, Mocharla R et al (2023) Accuracy of artificial intelligence in estimating best-corrected visual acuity from fundus photographs in eyes with diabetic macular edema. JAMA Ophthalmol 141:677\u2013685. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2271","journal-title":"JAMA Ophthalmol"},{"key":"6925_CR96","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00592-022-01941-9","volume":"59","author":"S Vujosevic","year":"2022","unstructured":"Vujosevic S, Limoli C, Luzi L al (2022) Digital innovations for retinal care in diabetic retinopathy. Acta Diabetol 59:1521\u20131530. https:\/\/doi.org\/10.1007\/s00592-022-01941-9","journal-title":"Acta Diabetol"},{"key":"6925_CR97","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/JCMA.0000000000000355","volume":"83","author":"DK Hwang","year":"2020","unstructured":"Hwang DK, Yu WK, Lin TC et al (2020) Smartphone-based diabetic macula edema screening with an offline artificial intelligence. J Chin Med Assoc 83:1102\u20131106. https:\/\/doi.org\/10.1097\/JCMA.0000000000000355","journal-title":"J Chin Med Assoc"},{"key":"6925_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-00319-x","volume":"3","author":"E Long","year":"2020","unstructured":"Long E, Chen J, Wu X et al (2020) Artificial intelligence manages congenital cataract with individualized prediction and telehealth computing. NPJ Digit Med 3:112. https:\/\/doi.org\/10.1038\/s41746-020-00319-x","journal-title":"NPJ Digit Med"},{"key":"6925_CR99","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.oret.2021.05.002","volume":"5","author":"M Gallardo","year":"2021","unstructured":"Gallardo M, Munk MR, Kurmann T et al (2021) Machine learning can predict Anti-VEGF treatment demand in a treat-and-extend regimen for patients with neovascular AMD, DME, and RVO associated macular edema. Ophthalmol Retina 5:604\u2013624. https:\/\/doi.org\/10.1016\/j.oret.2021.05.002","journal-title":"Ophthalmol Retina"},{"key":"6925_CR100","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/atm-20-1431","volume":"9","author":"B Liu","year":"2021","unstructured":"Liu B, Zhang B, Hu Y et al (2021) Automatic prediction of treatment outcomes in patients with diabetic macular edema using ensemble machine learning. Ann Transl Med 9:43. https:\/\/doi.org\/10.21037\/atm-20-1431","journal-title":"Ann Transl Med"},{"key":"6925_CR101","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1364\/BOE.379150","volume":"11","author":"R Rasti","year":"2020","unstructured":"Rasti R, Allingham MJ, Mettu PS et al (2020) Deep learning-based single-shot prediction of differential effects of anti-VEGF treatment in patients with diabetic macular edema. Biomed Opt Express 11:1139\u20131152. https:\/\/doi.org\/10.1364\/BOE.379150","journal-title":"Biomed Opt Express"},{"key":"6925_CR102","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.survophthal.2022.08.004","volume":"68","author":"MH Shahriari","year":"2023","unstructured":"Shahriari MH, Sabbaghi H, Asadi F et al (2023) Artificial intelligence in screening, diagnosis, and classification of diabetic macular edema: a systematic review. Surv Ophthalmol 68:42\u201353. https:\/\/doi.org\/10.1016\/j.survophthal.2022.08.004","journal-title":"Surv Ophthalmol"},{"key":"6925_CR103","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.4103\/ijo.IJO_1482_21","volume":"69","author":"S Chakroborty","year":"2021","unstructured":"Chakroborty S, Gupta M, Devishamani CS et al (2021) Narrative review of artificial intelligence in diabetic macular edema: diagnosis and predicting treatment response using optical coherence tomography. Indian J Ophthalmol 69:2999\u20133008. https:\/\/doi.org\/10.4103\/ijo.IJO_1482_21","journal-title":"Indian J Ophthalmol"},{"key":"6925_CR104","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00417-022-05942-w","volume":"261","author":"C Enders","year":"2023","unstructured":"Enders C, Duncker T, Sch\u00fcrks M et al (2023) See clearer: survey on the subjective and objective information levels as well as perception and information transfer using virtual reality headsets in patients with diabetic macular edema receiving anti-VEGF treatment. Graefes Arch Clin Exp Ophthalmol 261:1563\u20131570. https:\/\/doi.org\/10.1007\/s00417-022-05942-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6925_CR105","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000541349","volume":"68","author":"A Garc\u00eda-Layana","year":"2025","unstructured":"Garc\u00eda-Layana A, Chi GC, Kodjikian L et al (2025) Patient preferences with anti-Vascular endothelial growth factor treatment for neovascular age-eelated macular degeneration and diabetic macular edema: a multinational discrete choice experiment study. Ophthalmic Res 68:13\u201322. https:\/\/doi.org\/10.1159\/000541349","journal-title":"Ophthalmic Res"},{"key":"6925_CR106","doi-asserted-by":"publisher","first-page":"e000669","DOI":"10.1136\/bmjophth-2020-000669","volume":"6","author":"CK McClard","year":"2021","unstructured":"McClard CK, Wang R, Windham V et al (2021) Questionnaire to assess life impact of treatment by intravitreal injections (QUALITII): development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. BMJ Open Ophthalmol 6:e000669. https:\/\/doi.org\/10.1136\/bmjophth-2020-000669","journal-title":"BMJ Open Ophthalmol"},{"key":"6925_CR107","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/opo.12998","volume":"42","author":"S Sabharwal","year":"2022","unstructured":"Sabharwal S, Kuo KH, Roh S, Ramsey DJ (2022) An initiative to improve follow-up of patients with diabetic retinopathy. Ophthalmic Physiol Opt 42:965\u2013972. https:\/\/doi.org\/10.1111\/opo.12998","journal-title":"Ophthalmic Physiol Opt"},{"key":"6925_CR108","doi-asserted-by":"publisher","first-page":"e34669","DOI":"10.7759\/cureus.34669","volume":"15","author":"J Ting Yih Ling","year":"2023","unstructured":"Ting Yih Ling J, Mohd Zain A, Naffi AA et al (2023) Determination of factors influencing the health belief model (HBM) and adherence to intravitreal anti-vascular endothelial growth factor (VEGF) among patients with diabetic macular edema (DME). Cureus 15:e34669. https:\/\/doi.org\/10.7759\/cureus.34669","journal-title":"Cureus"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06925-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:03:31Z","timestamp":1770692611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06925-3"}},"subtitle":["The names of the authors"],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":108,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6925"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06925-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}